1.   Recognize the spectrum of rheumatologic immune-related adverse events (IRARs) associated with cancer immunotherapy

2.   Differentiate features of rheumatologic IRAEs from "traditional" rheumatic diseases

3.   Develop an approach to treatment for rheumatologic IRAEs in collaboration with oncologists

Session date: 
05/16/2017 - 8:30am to 9:30am CDT
UCMC N-002
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Clifton O. Bingham, M.D.